ESC 2023 | FIRE-Trial: Physiology Guided Complete Revascularization Benefits Elderly Patients with Myocardial Infarction

Patients over 75 with acute coronary syndrome (ACS) are often badly represented in most significant studies. 

ESC 2023

In this context, the FIRE study looked to determine whether physiology guided complete revascularization is superior to culprit-only revascularization in elderly patients with multivessel disease suffering acute MI. 

The study included SCA patients over 75, hospitalized for both STEMI and NSTEMI, who had received successful PCI of culprit lesion. These patients also presented multivessel disease with at least one lesion in a non-culprit vessel, minimum 2.5 mm in diameter and obstructed between 50% to 99%. 

After treating the culprit lesion, patients were randomized to culprit only treatment or physiology guided complete revascularization (PCI to lesions with positive functional tests). Primary end point was a composite of events including death, MI, stroke or new ischemia driven revascularization within one year. Secondary end point was a combination of cardiovascular death or MI at one year. Individual primary end components were also looked into. 

Read also: ESC 2023 | BUDAPEST CRT Upgrade trial.

The study looked at 1445 patients from 34 centers in Italy, Spain and Poland. Mean patient age was 80, and 36.5% were women. Primary end point was seen in 15.7% of patients undergoing physiology guided revascularization vs. 21% of patients receiving culprit only treatment (RR 0.73, CI 95%: 0.57-0.93; P=0.01). The number needed to treat (NNT) to prevent an event was 19 patients.

Each of this individual components of the primary end point seemed lower with physiology guided PCI, except for stroke, which resulted in reduced mortality (RR 0.64, CI 95%: 0.51-0.96) and NNT 27 patients to prevent death. There were no differences in safety outcomes. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presentado en Hot Line Sessions, agosto 26, ESC Congress 2023, Amsterdam.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...